Key Highlights
- Blackstone Life Sciences commits up to $750 million to fund Moderna’s influenza vaccine program.
- The partnership highlights a strategic move to advance mRNA vaccines for respiratory illnesses.
- Moderna aims to launch multiple vaccine products in the coming years, with Blackstone’s financing supporting late-stage studies.
- Potential milestones and royalties for BXLS upon successful development and commercialization of flu products.
- Moderna retains full rights and control over its influenza program, emphasizing the innovative financing model introduced by Blackstone.
Source: Business Wire
Notable Quotes
- “Moderna has demonstrated a remarkable ability to impact human health through mRNA vaccines targeting respiratory illnesses. This landmark collaboration is another example of our long-standing strategy to partner with the world’s leading life science companies.” – Nicholas Galakatos, Ph.D., Global Head at Blackstone Life Sciences
- “Moderna is advancing a broad and diverse pipeline at a pace not seen before in our industry. Our goal is to launch multiple vaccine products in the next few years.” – Stéphane Bancel, Chief Executive Officer at Moderna
SoHC's Take
This significant collaboration between Blackstone and Moderna represents a pivotal step forward in the fight against influenza. By leveraging Blackstone’s robust financing capabilities and Moderna’s innovative mRNA technology, this partnership aims to expedite the development and commercialization of new vaccines, marking a notable advancement in public health efforts. This strategic investment underscores the importance of collaborative efforts in advancing medical technology and highlights the ongoing commitment of both organizations to addressing critical healthcare challenges.
